

## YOUR ENHERTU RESOURCE GUIDE

- Efficacy & Safety
- Dosage & Administration
- Recommendations for Adverse Reaction Management

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) specifies fam-trastuzumab deruxtecan-nxki (ENHERTU) is preferred in patients with visceral metastases if progression on second-line ado-trastuzumab emtansine (T-DM1)<sup>1,a</sup>

<sup>a</sup>The guidelines note fam-trastuzumab deruxtecan (ENHERTU) may be used as a third- or fourth-line treatment option and optimal sequence for third-line therapy and beyond is not known.<sup>1</sup>

### Important Safety Information



#### Indication

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.


#### **WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY**

- **Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.**
- **Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.**

## ENHERTU is a specifically engineered HER2-directed antibody-drug conjugate (ADC)<sup>2,3</sup>

### HER2-directed mAb<sup>2</sup>

- Provides targeted delivery of cytotoxic agent<sup>2,3</sup>
- Consists of the same amino acid sequence as trastuzumab<sup>4</sup>



### Topoisomerase I inhibitor payload<sup>2,3,a</sup>

- Highly potent payload is an exatecan derivative, known as DXd, with a short systemic half-life<sup>2,4</sup>
- Upon release, membrane-permeable payload causes DNA damage and cell death, resulting in destruction of HER2+ tumor cells and surrounding cells of variable HER2 expression, known as the bystander antitumor effect<sup>2,4,5</sup>

### Tumor-selective cleavable linker<sup>2-4,a</sup>

- Attaches payload to the antibody<sup>2</sup>
- Linker-payload is stable in plasma<sup>3,4</sup>
- Linker selectively cleaved by enzymes that are upregulated in tumor cells<sup>2,4</sup>

**ENHERTU has a homogeneous and high drug-to-antibody ratio of ~8 molecules of cytotoxic agent per antibody<sup>2-4,a</sup>**

<sup>a</sup>Based on in vitro and in vivo non-clinical studies. The clinical relevance of these features is under investigation. DNA, deoxyribonucleic acid; HER2, human epidermal growth factor receptor 2; mAb, monoclonal antibody.

### Important Safety Information

#### Warnings and Precautions

#### Interstitial Lung Disease / Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).

## ENHERTU efficacy evaluated in DESTINY-Breast01

**184 female patients with unresectable and/or metastatic HER2+ breast cancer who had received two or more prior anti-HER2 therapies were studied in a Phase 2, multicenter, single-arm trial<sup>2,6</sup>**

- Patients received ENHERTU 5.4 mg/kg administered by IV infusion once every 3 weeks until unacceptable toxicity or disease progression

### Select baseline patient demographics and disease characteristics

- 100% had previous trastuzumab therapy<sup>2</sup>
- 66% had previous pertuzumab therapy<sup>2</sup>
- 100% had previous ado-trastuzumab emtansine therapy<sup>1</sup>
- Median age was 55 years (range: 28-96)<sup>2</sup>
- ECOG performance status at baseline was 0 in 55% and 1 in 44% of patients<sup>2</sup>
- 92% had presence of visceral disease<sup>2</sup>
- 57% had lung metastases<sup>7</sup>
- 30% had liver metastases<sup>7</sup>
- 29% had bone metastases<sup>2</sup>
- 13% had stable brain metastases<sup>2</sup>

<b>Primary endpoint<sup>1</sup></b>	<ul style="list-style-type: none"> <li>• Confirmed objective response rate (ORR), based on RECIST v1.1<sup>a</sup></li> </ul>
<b>Key secondary endpoints<sup>1,5</sup></b>	<ul style="list-style-type: none"> <li>• Overall survival (OS), duration of response (DOR), progression-free survival (PFS), disease control rate (DCR), clinical benefit rate (CBR) and best percent change in the sum of diameters of measurable tumors<sup>b</sup></li> </ul>

### Selected exclusion criteria<sup>2</sup>

- History of treated interstitial lung disease (ILD) or ILD at screening
- History of clinically significant cardiac disease
- Active brain metastases<sup>c</sup>
- ECOG performance status >1

**Multiple confirmatory Phase 3 studies are underway<sup>8</sup>**

<sup>a</sup>ORR defined as CR+PR per RECIST v1.1 in the ITT population as evaluated by ICR.<sup>2,6</sup> <sup>b</sup>DCR=CR+PR+SD; CBR=CR+PR+SD≥6 months.<sup>6</sup> <sup>c</sup>Patients with brain metastases who were untreated, symptomatic, or required therapy within 2 months of randomization were excluded. A prespecified number of patients with stable brain metastases were enrolled.<sup>7</sup>

CR, complete response; ECOG, Eastern Cooperative Oncology Group; ICR, independent central review; ITT, intent-to-treat IV, intravenous;; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

### Important Safety Information


#### Warnings and Precautions

#### Interstitial Lung Disease / Pneumonitis (continued)

Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level.

## ENHERTU monotherapy: efficacy results<sup>2</sup>

### Objective response rates (ORR) in DESTINY-Breast01<sup>2</sup>



### ENHERTU anti-tumor activity assessed in these select prespecified exploratory patient subgroups<sup>6,a,b</sup>

Presence of visceral metastases	
With visceral metastases	Without visceral metastases
<b>60% ORR</b> (n=102/169; 95% CI: 53, 68)	<b>67% ORR</b> (n=10/15; 95% CI: 38, 88)

Presence of brain metastases <sup>c</sup>	
With stable brain metastases	Without brain metastases
<b>58% ORR</b> (n=14/24; 95% CI: 37, 78)	<b>61% ORR</b> (n=98/160; 95% CI: 53, 69)

HR status	
HR+	HR-
<b>58% ORR</b> (n=56/97; 95% CI: 47, 68)	<b>66% ORR</b> (n=55/83; 95% CI: 55, 76)

<sup>a</sup>ORR defined as CR+PR per RECIST v1.1 in the ITT population as evaluated by ICR.<sup>2,6</sup> <sup>b</sup>Data based on cutoff date of August 1, 2019. <sup>c</sup>Patients with stable (asymptomatic and previously treated) brain metastases. Brain lesions were non-target lesions.<sup>6</sup> CI, confidence interval; HR, hormone receptor.

### Important Safety Information


#### Warnings and Precautions

#### Interstitial Lung Disease / Pneumonitis (continued)

Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g.,  $\geq 0.5$  mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g.,  $\geq 1$  mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.

## ENHERTU monotherapy: efficacy results<sup>2</sup>

Median duration of response (mDOR) in DESTINY-Breast01<sup>2</sup>



<sup>a</sup>Median DOR based on Kaplan-Meier estimate. DOR based on a median duration of follow-up of 11.1 months.<sup>2</sup>

### Important Safety Information


#### Warnings and Precautions

##### Neutropenia

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 62% of patients. Sixteen percent had Grade 3 or 4 decrease in neutrophil count. Median time to first onset of decreased neutrophil count was 23 days (range: 6 to 547). Febrile neutropenia was reported in 1.7% of patients.

## Median PFS of 16.4 months demonstrated in DESTINY-Breast01<sup>6</sup>

Probability of PFS for patients with HER2+ unresectable or mBC receiving ENHERTU 5.4 mg/kg (N=184)<sup>6,a</sup>



No. at risk: 184 182 174 155 153 135 121 107 103 94 69 54 38 17 11 10 9 4 3 1 0

<sup>a</sup>Of the 184 patients, 48 had progressive disease and 10 had died by 20 months; data for 126 patients were censored, as indicated by tick marks. Disease progression was assessed using modified RECIST v1.1. Dashed lines indicate the 95% CI. Based upon median duration of follow-up of 11.1 months at data cutoff date of August 1, 2019.<sup>6</sup>

**18.1 months median PFS**  
(95% CI: 6.7, 18.1)

in a prespecified exploratory subgroup analysis of 24 patients with stable brain metastases<sup>6</sup>

**Median overall survival was not reached in DESTINY-Breast01 at median follow-up of 11.1 months, data cutoff August 1, 2019<sup>6</sup>**

- ENHERTU received accelerated approval from FDA based on tumor response rate and duration of response. FDA has not reviewed the PFS and OS data. Multiple confirmatory Phase 3 studies are underway<sup>8</sup>

FDA, Food and Drug Administration; mBC, metastatic breast cancer.

### Important Safety Information

#### Warnings and Precautions


#### Neutropenia (continued)

Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 10<sup>9</sup>/L) interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 10<sup>9</sup>/L) interrupt ENHERTU until resolved to Grade 2 or less. Reduce dose by one level. For febrile neutropenia (ANC <1.0 x 10<sup>9</sup>/L and temperature >38.3°C or a sustained temperature of ≥38°C for more than 1 hour), interrupt ENHERTU until resolved. Reduce dose by one level.



## The majority of patients experienced a reduction in tumor size with ENHERTU<sup>6</sup>

### Best percent change from baseline in sum of diameters of target lesions by ICR<sup>6,a</sup>



<sup>a</sup>Numbers based on patients treated with ENHERTU 5.4 mg/kg Q3W who had both baseline and postbaseline target lesions assessed by ICR (n=168). For each subject, the minimum (best) percent change from baseline in the sum of the diameters for all target lesions is represented by a vertical line.<sup>6</sup>

**97.3%**  
**DCR**

**Disease control rate<sup>6</sup>**  
DCR=CR+PR+SD  
(n=179/184; 95% CI: 93.8, 99.1)

**76.1%**  
**CBR**

**Clinical benefit rate<sup>6</sup>**  
CBR=CR+PR+SD $\geq$ 6 months  
(n=140/184; 95% CI: 69.3, 82.1)

Q3W, every three weeks.

### Important Safety Information

#### Warnings and Precautions

##### Left Ventricular Dysfunction

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, two cases (0.9%) of asymptomatic LVEF decrease were reported. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

## ENHERTU safety evaluated in a pooled analysis<sup>2</sup>

### The majority of adverse reactions were Grade 1 or 2<sup>2</sup>

The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2+ breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in Phase 2 DESTINY-Breast01 and Phase 1 Study DS8201-A-J101<sup>2</sup>

- Median duration of treatment was 7 months (range: 0.7-31)<sup>2</sup>
- 94% of patients had visceral disease<sup>2</sup>
- 31% of patients had bone metastases<sup>2</sup>
- 13% of patients had brain metastases<sup>2</sup>

### Common adverse reactions (≥10% all Grades or ≥2% Grades 3 or 4)<sup>2</sup>

Adverse Reactions		ENHERTU 5.4 mg/kg (N=234)	
		All Grades (%)	Grade 3 or 4 (%)
Gastrointestinal Disorders	Nausea	79	7
	Vomiting	47	3.8
	Constipation	35	0.9
	Diarrhea	29	1.7
	Abdominal pain <sup>a</sup>	19	1.3
	Stomatitis <sup>b</sup>	14	0.9
	Dyspepsia	12	0
General Disorders and Administration Site Conditions	Fatigue <sup>c</sup>	59	6
Skin and Subcutaneous Tissue Disorders	Alopecia	46	0.4 <sup>d</sup>
	Rash <sup>e</sup>	10	0
Metabolism and Nutrition Disorders	Decreased appetite	32	1.3
Blood and Lymphatic System Disorders	Anemia <sup>f</sup>	31	7
Respiratory, Thoracic, and Mediastinal Disorders	Cough	20	0
	Dyspnea	13	1.3
	Epistaxis	13	0
	Interstitial lung disease <sup>g</sup>	9	2.6 <sup>h</sup>

Events were graded using NCI-CTCAE version 4.03. N, number of patients exposed; PT, preferred term. Percentages were calculated using the number of patients in the Safety Analysis Set as the denominator. <sup>a</sup>Grouped term of abdominal pain includes PTs of abdominal discomfort, gastrointestinal pain, abdominal pain, abdominal pain lower, and abdominal pain upper. <sup>b</sup>Grouped term of stomatitis includes PTs of stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosa blistering. One Grade 1 event of aphthous ulcer was not included in the summary of grouped term stomatitis (from DESTINY-Breast01). <sup>c</sup>Grouped term of fatigue includes PTs of fatigue and asthenia. <sup>d</sup>This Grade 3 event was reported by the investigator. Per NCI-CTCAE v.4.03, the highest NCI-CTCAE grade for alopecia is Grade 2. <sup>e</sup>Grouped term of rash includes PTs of rash, rash pustular, rash maculo-papular. <sup>f</sup>Grouped term of anemia includes PTs of anemia, hemoglobin decreased, hematocrit decreased, and red blood cell count decreased. <sup>g</sup>Interstitial lung disease includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, alveolitis. <sup>h</sup>All events had fatal outcomes (n=6).

table continues >



## ENHERTU safety evaluated in a pooled analysis<sup>2</sup>

### Common adverse reactions (≥10% all Grades or ≥2% Grades 3 or 4) (continued)<sup>2</sup>

Adverse Reactions		ENHERTU 5.4 mg/kg (N=234)	
		All Grades (%)	Grade 3 or 4 (%)
Nervous System Disorders	Headache <sup>a</sup>	19	0
	Dizziness	10	0
Infections and Infestation	Upper respiratory tract infection <sup>b</sup>	15	0
Eye Disorders	Dry eye	11	0.4 <sup>c</sup>

<sup>a</sup>Grouped term of headache includes PTs of headache, sinus headache, and migraine. <sup>b</sup>Grouped term of upper respiratory tract infection includes PTs of influenza, influenza like illness, upper respiratory tract infection. <sup>c</sup>This Grade 4 event was reported by the investigator. Per NCI-CTCAE v.4.03, the highest NCI-CTCAE grade for dry eye is Grade 3.

### Selected laboratory abnormalities reported in patients with HER2+ unresectable or mBC in the pooled analysis<sup>2</sup>

Laboratory Parameter		ENHERTU 5.4 mg/kg (N=234)	
		All Grades (%)	Grade 3 or 4 (%)
Hematology	White blood cell count decreased	70	7
	Hemoglobin decreased	70	7
	Neutrophil count decreased	62	16
	Platelet count decreased	37	3.4
Chemistry	Aspartate aminotransferase increased	41	0.9
	Alanine aminotransferase increased	38	0.4
	Hypokalemia	26	3

Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI-CTCAE v.4.03 grade-derived laboratory abnormalities.

## ENHERTU dosage and administration

### Recommended weight-based dosage and schedule<sup>2</sup>

- ENHERTU is always given as a monotherapy
- ENHERTU mBC dosage (5.4 mg/kg) differs from other approved indication



Until disease progression or unacceptable toxicity<sup>2</sup>

- **Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine**
- Slow or interrupt the infusion rate if the patient develops infusion-related symptoms
- Permanently discontinue ENHERTU in case of severe infusion reactions

### Dosage forms and strengths

- For injection: 100 mg of ENHERTU as a white to yellowish-white lyophilized powder in a single-dose vial for reconstitution and further dilution

See Preparation for Administration on pages 12 and 13.



## Dose modifications<sup>2</sup>

Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of ENHERTU per dose modifications provided in the table below.

- **Do not re-escalate the ENHERTU dose after a dose reduction is made**

### If a planned dose is delayed or missed

- ENHERTU should be administered as soon as possible; do not wait until the next planned cycle
- Adjust the schedule of administration to maintain a 3-week interval between doses
- Administer the infusion at the dose and rate the patient tolerated in the most recent infusion

### Recommended dose reductions for ENHERTU for adverse reactions<sup>2</sup>

Dose reduction schedule	Metastatic Breast Cancer Starting Dose 5.4 mg/kg
First dose reduction	4.4 mg/kg
Second dose reduction	3.2 mg/kg
Requirement for further dose reduction	Discontinue treatment

## ENHERTU preparation for administration<sup>2</sup>

In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU and not trastuzumab or ado-trastuzumab emtansine.<sup>2</sup>

Reconstitute and further dilute ENHERTU prior to intravenous infusion. Use appropriate aseptic technique.<sup>2</sup>

ENHERTU is a cytotoxic drug. Follow applicable special handling and disposal procedures.<sup>9</sup>

### Reconstitution<sup>2</sup>



- Reconstitute immediately before dilution
- More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed
- Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL
- Swirl the vial gently until completely dissolved. **Do not shake**
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored
- If not used immediately, store the reconstituted ENHERTU vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution, protected from light. **Do not freeze**
- The product does not contain a preservative. Discard unused ENHERTU after 24 hours refrigerated


## ENHERTU preparation for administration<sup>2</sup> (continued)

### Dilution<sup>2</sup>



- Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP. **Do not use sodium chloride solution, USP.** ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene)
- Gently invert the infusion bag to thoroughly mix the solution. **Do not shake**
- Cover the infusion bag to protect from light
- If not used immediately, store at room temperature for up to 4 hours including preparation and infusion, or in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours, protected from light. **Do not freeze**
- Discard any unused portion left in the vial

### Administration<sup>2</sup>



- If the prepared infusion solution was stored refrigerated (2°C to 8°C [36°F to 46°F]), allow the solution to reach room temperature prior to administration
- Administer ENHERTU as an intravenous infusion only with an infusion set made of polyolefin or polybutadiene and a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter. Do not administer as an intravenous push or bolus
- Do not mix ENHERTU with other drugs or administer other drugs through the same intravenous line

## Other adverse reactions in pooled analysis of patients treated with ENHERTU 5.4 mg/kg (N=234)<sup>2</sup>

Other clinically relevant **adverse reactions reported in <10%** of patients were:

- *Injury, Poisoning and Procedural Complications*: **infusion-related reactions (2.6%)**
- *Blood and Lymphatic System Disorders*: **febrile neutropenia (1.7%)**

**Serious adverse reactions occurred in 20%** of patients receiving ENHERTU.

Serious adverse reactions in >1% of patients included:

- Interstitial lung disease
- Pneumonia
- Vomiting
- Nausea
- Cellulitis
- Hypokalemia
- Intestinal obstruction

**Fatalities due to adverse reactions occurred in 4.3%** of patients:

- Interstitial lung disease (2.6%)
- Acute hepatic failure/acute kidney injury (0.4%)
- General physical health deterioration (0.4%)
- Pneumonia (0.4%)
- Hemorrhagic shock (0.4%)



## Adverse reactions may require dose discontinuation, interruption, or reduction<sup>2</sup>

**9%**

### Discontinuation

Due to Adverse Reactions

- The most frequent adverse reaction associated with permanent discontinuation was ILD (6%)
- Permanently discontinue ENHERTU in patients who are diagnosed with any symptomatic (Grade 2 or greater) ILD

**33%**

### Dose Interruptions

Due to Adverse Reactions

- The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, thrombocytopenia, leukopenia, upper respiratory tract infection, fatigue, nausea, and ILD

**18%**

### Dose Reductions

Due to Adverse Reactions

- The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, and neutropenia

### Most common adverse reactions (≥20%), including laboratory abnormalities

- Nausea (79%)
- White blood cell count decreased (70%)
- Hemoglobin decreased (70%)
- Neutrophil count decreased (62%)
- Fatigue (59%)
- Vomiting (47%)
- Alopecia (46%)
- Aspartate aminotransferase increased (41%)
- Alanine aminotransferase increased (38%)
- Platelet count decreased (37%)
- Constipation (35%)
- Decreased appetite (32%)
- Anemia (31%)
- Diarrhea (29%)
- Hypokalemia (26%)
- Cough (20%)

## Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU; monitor patients and initiate management at first sign of ILD<sup>2,a</sup>

- Severe, life-threatening, or fatal ILD, including pneumonitis can occur in patients treated with ENHERTU<sup>2</sup>
- In clinical studies, of the 234 patients with HER2+ unresectable or mBC treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients (n=22/234)<sup>2,7</sup>
  - Majority of ILD events were Grade 2 (n=12/22)<sup>7</sup>
  - Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients<sup>2</sup>
- Median time to first onset was 4.1 months (range: 1.2-8.3)<sup>2</sup>

**ENHERTU Prescribing Information management recommendations for ILD/pneumonitis, including corticosteroid recommendations, were based on experience in the clinical trials and developed in collaboration with an external ILD expert panel comprised of oncologists, pulmonologists, and radiologists**

<sup>a</sup>Interstitial lung disease includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, alveolitis.

### Promptly investigate evidence of ILD/pneumonitis<sup>2</sup>

- Evaluate patients with suspected ILD by radiographic imaging<sup>2</sup>
- Consider consultation with a pulmonologist<sup>2</sup>
- Investigation may be prompted by incidental findings on routine scans when checking for progression or symptomatic findings
  - Diagnosis of ILD requires exclusion of other causes

### For asymptomatic ILD/pneumonitis (Grade 1)<sup>2</sup>

- Consider corticosteroid treatment (eg, ≥0.5 mg/kg/day prednisolone or equivalent)
- Interrupt ENHERTU until resolved to Grade 0, then:
  - If resolved in 28 days or less from date of onset, maintain dose
  - If resolved in greater than 28 days from date of onset, reduce dose one level (see table on page 11)

### For symptomatic ILD/pneumonitis (Grade 2 or greater)<sup>2</sup>

- Promptly initiate systemic corticosteroid treatment (eg, ≥1 mg/kg/day prednisolone or equivalent)
  - Continue for at least 14 days followed by gradual taper for at least 4 weeks
- Permanently discontinue ENHERTU in patients who are diagnosed with any symptomatic ILD/pneumonitis

## Symptom identification is key to ILD/pneumonitis diagnosis

### Monitor patients for and promptly investigate the signs and symptoms of ILD, which may include<sup>2</sup>:

- Cough
- Dyspnea
- Fever
- New or worsening respiratory symptoms

### Talk to your patients to raise awareness and help identify symptoms<sup>2</sup>

- Advise patients to contact their healthcare provider immediately for any of the symptoms shown above
- Inform patients of the risks of severe, life-threatening, or fatal ILD
- Advise patients to read the FDA-approved patient labeling (Medication Guide)



### Potential questions to ask your patients to help with early identification of ILD<sup>10,11</sup>

- Have you been coughing recently? Is it a dry cough?
- Have you had any shortness of breath, especially during or after physical activity?
- Have you experienced any new breathing or respiratory problems?
- If you already have respiratory problems, have they gotten worse?
- Have you had a fever?
- Have you been feeling tired?
- Have you lost weight?

**Talk with your patients about the potential benefits and risks of treatment with ENHERTU**

## Management of neutropenia with ENHERTU<sup>2</sup>

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU.

- Of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 62% of patients and 16% percent had Grade 3 or 4 decrease in neutrophil count. Febrile neutropenia was reported in 1.7% of patients
- Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated
- Based on the severity of neutropenia, manage through treatment interruption or dose reduction

### Dose modifications for neutropenia<sup>2</sup>

Severity	Treatment Modification
Grade 3 (less than 1.0 to 0.5 x 10 <sup>9</sup> /L)	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose</li> </ul>
Grade 4 (less than 0.5 x 10 <sup>9</sup> /L)	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU until resolved to Grade 2 or less</li> <li>• Reduce dose by one level (see Dose Modifications for Adverse Reactions on page 11)</li> </ul>

Toxicity grades are in accordance with the National Cancer Institute – Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

### Dose modifications for febrile neutropenia<sup>2</sup>

Severity	Treatment Modification
Absolute neutrophil count of less than 1.0 x 10 <sup>9</sup> /L and temperature greater than 38.3°C or a sustained temperature of ≥38°C for more than 1 hour	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU until resolved</li> <li>• Reduce dose by one level (see Dose Modifications for Adverse Reactions on page 11)</li> </ul>

Toxicity grades are in accordance with the National Cancer Institute – Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

## Management of thrombocytopenia with ENHERTU<sup>2</sup>

Thrombocytopenia can occur in patients treated with ENHERTU.<sup>2</sup>

- Of the 184 patients with unresectable or metastatic HER-2 positive breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast01, the incidence of platelet count decrease<sup>7</sup>
  - Grade 1 incidence 9.8%; Grade 2 incidence 4.3%; Grade 3 incidence 3.3%
- Based on the severity of thrombocytopenia, manage through treatment interruption or dose reduction<sup>2</sup>

### Dose modifications for thrombocytopenia<sup>2</sup>

Severity	Treatment Modification
Grade 3 (platelets less than 50 to 25 x 10 <sup>9</sup> /L)	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose</li> </ul>
Grade 4 (platelets less than 25 x 10 <sup>9</sup> /L)	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU until resolved to Grade 1 or less</li> <li>• Reduce dose by one level (see Dose Modifications for Adverse Reactions on page 11)</li> </ul>

Toxicity grades are in accordance with the National Cancer Institute – Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

## Management of left ventricular dysfunction with ENHERTU<sup>2</sup>

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU.

- In the 234 patients with unresectable or metastatic HER2+ breast cancer who received ENHERTU 5.4 mg/kg, two cases (0.9%) of asymptomatic LVEF decrease were reported
- Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated
- Manage through treatment interruption or discontinuation

### Dose modifications for left ventricular dysfunction<sup>2</sup>

Severity		Treatment Modification
LVEF greater than 45% and absolute decrease from baseline is 10% to 20%		<ul style="list-style-type: none"> <li>• Continue treatment with ENHERTU</li> </ul>
LVEF 40% to 45%	And absolute decrease from baseline is less than 10%	<ul style="list-style-type: none"> <li>• Continue treatment with ENHERTU</li> <li>• Repeat LVEF assessment within 3 weeks</li> </ul>
	And absolute decrease from baseline is 10% to 20%	<ul style="list-style-type: none"> <li>• Interrupt ENHERTU</li> <li>• Repeat LVEF assessment within 3 weeks</li> <li>• If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU</li> <li>• If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose</li> </ul>
LVEF less than 40% or absolute decrease from baseline is greater than 20%		<ul style="list-style-type: none"> <li>• Interrupt ENHERTU</li> <li>• Repeat LVEF assessment within 3 weeks</li> <li>• If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue ENHERTU</li> </ul>
Symptomatic congestive heart failure (CHF)		<ul style="list-style-type: none"> <li>• Permanently discontinue ENHERTU</li> </ul>

Toxicity grades are in accordance with the National Cancer Institute – Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).



## Nausea: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	41.3%
Grade 2	28.3%
Grade 3	7.6%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 65.2% of patients**

**Cycle 2 = 28% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, prophylaxis use, patient discontinuations, dose modifications, etc.
- Prophylaxis and treatment<sup>7</sup>
  - 70.1% of patients received an antiemetic and/or antinauseant as prophylaxis or for treatment of nausea
  - Available data did not allow for differentiation between prophylaxis use and treatment of nausea

- The median duration of the first event of nausea was 8.0 days (range: 1-323)<sup>7</sup>
- 34.8% of patients had 1 event of nausea, 13.6% had 2 events, and 28.8% had >2 events<sup>7</sup>

**No patients discontinued treatment due to nausea.  
Dose interruption was required in 1.6% of patients and 2.7% required dose reduction<sup>7</sup>**

## Vomiting: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	27.2%
Grade 2	14.1%
Grade 3	3.8%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 27.2% of patients**

**Cycle 2 = 14.8% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, prophylaxis use, patient discontinuations, dose modifications, etc.
- Prophylaxis and treatment<sup>7</sup>
  - 70.1% of patients received an antiemetic and/or antinauseant as prophylaxis or for treatment of vomiting
  - Available data did not allow for differentiation between prophylaxis use and treatment of vomiting

- The median duration of the first event of vomiting was 3.0 days (range: 1-215)<sup>7</sup>
- 23.4% of patients had 1 event of vomiting, 7.1% had 2 events, and 14.7% had >2 events<sup>7</sup>

**No patients discontinued treatment due to vomiting.  
Dose interruption was required in 1.1% of patients and 1.6% required dose reduction<sup>7</sup>**

## Fatigue: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	22.3%
Grade 2	20.1%
Grade 3	5.4%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 29.3% of patients**

**Cycle 2 = 11.5% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, patient discontinuations, dose modifications, etc.
- The median duration of the first event of fatigue was 15.0 days (range: 1-207)<sup>7</sup>
- 32.1% of patients had 1 event of fatigue, 7.6% had 2 events, and 8.2% had >2 events<sup>7</sup>

**No patients discontinued treatment due to fatigue.**

**Dose interruption was required in 1.6% of patients and 3.3% required dose reduction<sup>7</sup>**

## Alopecia: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1 <sup>a</sup>	36.4%
Grade 2 <sup>b,c</sup>	10.9%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 14.7% of patients**

**Cycle 2 = 13.2% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, patient discontinuations, dose modifications, etc.

<sup>a</sup>Grade 1: Hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage.<sup>12</sup> <sup>b</sup>Grade 2: Hair loss of ≥50% of normal that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact.<sup>12</sup> <sup>c</sup>Per NCI-CTCAE v.4.03, the highest NCI-CTCAE grade for alopecia was Grade 2. 0.5% Grade 3 alopecia (1 patient) was reported by investigators.<sup>7</sup>

**No patients discontinued treatment due to alopecia.  
No patients required dose interruption or dose reduction<sup>7</sup>**

## Constipation: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	26.6%
Grade 2	7.1%
Grade 3	0.5%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 15.8% of patients**

**Cycle 2 = 8.2% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, prophylaxis use, patient discontinuations, dose modifications, etc.
- Prophylaxis and treatment<sup>7</sup>
  - 39.7% of patients received medication for constipation
  - Available data did not allow for differentiation between prophylaxis use and treatment of constipation

- The median duration of the first event of constipation was 15.0 days (range: 1-180)<sup>7</sup>
- 25.5% of patients had 1 event of constipation, 5.4% had 2 events, and 3.3% had >2 events<sup>7</sup>

**No patients discontinued treatment due to constipation.  
No patients required dose interruption or dose reduction<sup>7</sup>**

## Diarrhea: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	16.8%
Grade 2	8.2%
Grade 3	1.6%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 10.9% of patients**

**Cycle 2 = 7.1% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, prophylaxis use, patient discontinuations, dose modifications, etc.
- Prophylaxis and treatment<sup>7</sup>
  - 19.6% of patients received medication for the treatment of diarrhea
  - Available data did not allow for differentiation between prophylaxis use and treatment of diarrhea

- The median duration of the first event of diarrhea was 4.0 days (range: 1-99)<sup>7</sup>
- 17.4% of patients had 1 event of diarrhea, 7.1% had 2 events, and 2.2% had >2 events<sup>7</sup>

**No patients discontinued treatment due to diarrhea.  
Dose interruption was required in 1.1% of patients and 0.5% required dose reduction<sup>7</sup>**



## Decreased appetite: Incidence in DESTINY-Breast01 in patients treated with ENHERTU (5.4 mg/kg; N=184)<sup>2,7</sup>

Grade	Incidence
Grade 1	20.1%
Grade 2	7.1%
Grade 3	1.6%
Grade 4	0%

### Incidence decreased by cycle<sup>7</sup>

**Cycle 1 = 17.4% of patients**

**Cycle 2 = 4.9% of patients**

- Rates decreased in subsequent cycles<sup>7</sup>
  - No conclusions may be drawn on whether the decreased rates are due to increased tolerance, prophylaxis use, patient discontinuations, dose modifications, etc.
- Prophylaxis and treatment<sup>7</sup>
  - 1.6% of patients received appetite stimulants
  - Available data did not allow for differentiation between prophylaxis use and treatment of decreased appetite

- The median duration of the first event of decreased appetite was 16.0 days (range: 2-288)<sup>7</sup>
- 20.7% of patients had 1 event of decreased appetite, 4.3% had 2 events, and 3.8% had >2 events<sup>7</sup>

**No patients discontinued treatment due to decreased appetite.  
Dose interruption was required in 0% of patients and 1.1% required dose reduction<sup>7</sup>**

**ENHERTU**<sup>®</sup>  
fam-trastuzumab deruxtecan-nxki  
20 mg/mL INJECTION FOR INTRAVENOUS USE



## ENHERTU4U provides support resources for patients prescribed ENHERTU



### Access

Support options are available to help your patients access ENHERTU. Enroll today for help with benefit verifications, understanding prior authorization requirements, and more



### Affordability Options

We have multiple options to help your patients afford their treatment. Visit ENHERTU4U.com for programs and enrollment information

**ENHERTU4U does not guarantee access or cost savings for patients prescribed ENHERTU. Restrictions apply.**

To enroll your patients visit **ENHERTU4U.com**  
or **call 1-833-ENHERTU** (1-833-364-3788)

## Important Safety Information

### Indication

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

### **WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY**

- **Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.**
- **Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.**

### Contraindications

None.

### Warnings and Precautions

#### Interstitial Lung Disease / Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).

Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in  $\leq 28$  days from date of onset, maintain dose. If resolved in  $> 28$  days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g.,  $\geq 0.5$  mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g.,  $\geq 1$  mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.

## Important Safety Information (continued)

### Neutropenia

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 62% of patients. Sixteen percent had Grade 3 or 4 decrease in neutrophil count. Median time to first onset of decreased neutrophil count was 23 days (range: 6 to 547). Febrile neutropenia was reported in 1.7% of patients.

Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC]  $<1.0$  to  $0.5 \times 10^9/L$ ) interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC  $<0.5 \times 10^9/L$ ) interrupt ENHERTU until resolved to Grade 2 or less. Reduce dose by one level. For febrile neutropenia (ANC  $<1.0 \times 10^9/L$  and temperature  $>38.3^\circ C$  or a sustained temperature of  $\geq 38^\circ C$  for more than 1 hour), interrupt ENHERTU until resolved. Reduce dose by one level.

### Left Ventricular Dysfunction

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, two cases (0.9%) of asymptomatic LVEF decrease were reported. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF  $<50\%$  prior to initiation of treatment.

Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. When LVEF is  $>45\%$  and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is  $<10\%$ , continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is  $<40\%$  or absolute decrease from baseline is  $>20\%$ , interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of  $<40\%$  or absolute decrease from baseline of  $>20\%$  is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure.

### Embryo-Fetal Toxicity

ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months after the last dose of ENHERTU.

### Additional Dose Modifications

#### Thrombocytopenia

For Grade 3 thrombocytopenia (platelets  $<50$  to  $25 \times 10^9/L$ ) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets  $<25 \times 10^9/L$ ) interrupt ENHERTU until resolved to Grade 1 or less. Reduce dose by one level.

## Important Safety Information (continued)

### Adverse Reactions

The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 7 months (range: 0.7 to 31).

Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease, pneumonia, vomiting, nausea, cellulitis, hypokalemia, and intestinal obstruction. Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock.

ENHERTU was permanently discontinued in 9% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 33% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, thrombocytopenia, leukopenia, upper respiratory tract infection, fatigue, nausea, and ILD. Dose reductions occurred in 18% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, and neutropenia.

The most common ( $\geq 20\%$ ) adverse reactions, including laboratory abnormalities, were nausea (79%), white blood cell count decreased (70%), hemoglobin decreased (70%), neutrophil count decreased (62%), fatigue (59%), vomiting (47%), alopecia (46%), aspartate aminotransferase increased (41%), alanine aminotransferase increased (38%), platelet count decreased (37%), constipation (35%), decreased appetite (32%), anemia (31%), diarrhea (29%), hypokalemia (26%), and cough (20%).

### Use in Specific Populations

- **Pregnancy:** ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months following the last dose of ENHERTU.
- **Lactation:** There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
- **Females and Males of Reproductive Potential:** Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: *Females:* ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 7 months following the last dose. *Males:* Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months following the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
- **Pediatric Use:** Safety and effectiveness of ENHERTU have not been established in pediatric patients.
- **Geriatric Use:** Of the 234 patients with HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, 26% were  $\geq 65$  years and 5% were  $\geq 75$  years. No overall differences in efficacy were observed between patients  $\geq 65$  years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged  $\geq 65$  years (53%) as compared to younger patients (42%).
- **Hepatic Impairment:** In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor.

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or [fda.gov/medwatch](http://fda.gov/medwatch).



# ENHERTU<sup>®</sup>

fam-trastuzumab deruxtecan-nxki  
20 mg/mL INJECTION FOR INTRAVENOUS USE

Learn more at [ENHERTUhcp.com/breast](https://ENHERTUhcp.com/breast)

Please see Important Safety Information throughout as well as on pages 29-31, and [click here for full Prescribing Information](#), including Boxed WARNINGS, and [click here for Medication Guide](#).

**References:** **1.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 31, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. **2.** ENHERTU [prescribing information]. Daiichi Sankyo Inc., Basking Ridge, NJ and AstraZeneca Pharmaceuticals LP, Wilmington, DE, 2021. **3.** Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clin Cancer Res.* 2016;22(20):5097-5108. **4.** Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. *Chem Pharm Bull (Tokyo).* 2019;67(3):173-185. **5.** Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. *Cancer Sci.* 2016;107(7):1039-1046. **6.** Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med.* 2020;382(7):610-621. **7.** Data on file. Daiichi Sankyo Inc., Basking Ridge, NJ. **8.** FDA filing Letter DS8201. August 29, 2019. Daiichi Sankyo, Inc. **9.** OSHA Hazardous Drugs. OSHA. <http://www.osha.gov/SLTC/hazardousdrugs/index.html>. **10.** Ripley BA, Kelil T, Gill RR. Deciphering drug-induced interstitial lung disease. A mechanistic approach. *Appl Radiol.* 2016;45(4):9-18. **11.** Kubo K, Azuma A, Kanazawa M, et al; Japanese Respiratory Society Committee. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. *Respir Investig.* 2013;51(4):260-277. **12.** National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. NIH publication 09-5410. Published May 28, 2009; Revised June 14, 2010.



ENHERTU<sup>®</sup> is a registered trademark of Daiichi Sankyo Company, Limited.  
© 2021 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-0657 04/21